share_log

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $47

Benzinga ·  May 3 09:33

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $48 to $47.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment